GPC Biotech and Lilly Join Forces for Drug Discovery
By Biotechdaily staff writers
Posted on 13 Feb 2003
A collaboration for drug discovery in metabolic diseases has been announced by GPC Biotech AG (Martinsried, Germany) and Eli Lilly & Company (Indianapolis, IN, USA). Posted on 13 Feb 2003
Under the terms of their agreement, GPC Biotech will use its LeadCode technology to elucidate the mechanism of action of a class of compounds being developed by Lilly for metabolic diseases. LeadCode is a drug-target interaction screening technology that can be applied across a broad range of compounds and disease areas. The technology is designed to identify and analyze the interaction of a small molecule, such as a drug, with the full complement of human proteins. LeadCode is part of GPC Biotech's Reverse Genomics platform, which focuses on addressing issues at later stages of the drug discovery process and uses discovery technologies to understand how drugs impact the body.
"We developed LeadCode to address key bottlenecks and reduce attrition in pharmaceutical drug discovery programs across a broad range of therapeutic areas,” said Bernd R. Seizinger, M.D., Ph.D., president and CEO of GPC Biotech. "We are delighted to have the opportunity to work with Eli Lilly and Company, our first US pharmaceutical partner and a recognized world leader in drug discovery and development.”
Related Links:
GPC Biotech
Eli Lilly
Gold Member
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
